Webcast

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

Source: Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors


CME Program Director: Joseph J. Eron, Jr., MD

Faculty:

  • Joel E. Gallant, MD, MPH

CME CREDIT INFORMATION

Release Date: 05/02/06

Expiration Date: 05/01/07


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the need for novel antiretroviral agents
  • Describe recent data on agents in novel classes, including chemokine coreceptor antagonists and integrase inhibitors
  • Review the clinical settings in which novel antiretroviral agents may find application

CCO Webcasts combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.